U.S. Markets closed

Neovasc (NVCN) Looks Good: Stock Adds 7.4% in Session

Zacks Equity Research
1 / 2

EMCOR's (EME) Q3 Earnings and Revenues Beat, Guidance Raised

EMCOR's (EME) solid third-quarter 2018 results were driven by improved margins across all segments

Neovasc Inc. NVCN was a big mover last session, as the company saw its shares rise more than 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, trading within a volatile range of $2.00–$4.00 in the past one-month time frame, showed a sharp increase yesterday.

The company has seen no changes when it comes to estimate revision over the past month, while the Zacks Consensus Estimate for the current quarter has also remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Neovasc currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.

Neovasc Inc. Price

Neovasc Inc. Price | Neovasc Inc. Quote

A better-ranked stock in the Medical - Instruments industry is Mesa Laboratories, Inc. MLAB, which currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Is NVCN going up? Or down? Predict to see what others think:Up or Down
 
5 Medical Stocks to Buy Now
 
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
 
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
 
Click here to see the 5 stocks >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Neovasc Inc. (NVCN) : Free Stock Analysis Report
 
Mesa Laboratories, Inc. (MLAB) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research